Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Foghorn Therapeutics Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
FHTX
Nasdaq
2830
foghorntx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Foghorn Therapeutics Inc.
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
- Feb 11th, 2025 2:24 pm
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
- Feb 9th, 2025 11:12 am
Techne (TECH) Tops Q2 Earnings and Revenue Estimates
- Feb 5th, 2025 12:45 pm
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
- Feb 3rd, 2025 2:03 pm
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Jan 15th, 2025 2:35 pm
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
- Jan 13th, 2025 12:00 pm
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
- Jan 9th, 2025 5:00 pm
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright
- Dec 18th, 2024 11:25 am
Foghorn Therapeutics Advances Precision Oncology Pipeline
- Dec 17th, 2024 12:29 pm
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
- Dec 16th, 2024 12:00 pm
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
- Dec 12th, 2024 2:35 pm
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
- Nov 29th, 2024 5:00 pm
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
- Nov 25th, 2024 2:55 pm
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
- Nov 12th, 2024 12:54 pm
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report
- Nov 7th, 2024 1:07 pm
We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully
- Nov 6th, 2024 11:59 am
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
- Nov 4th, 2024 10:25 pm
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
- Nov 4th, 2024 9:05 pm
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
- Oct 23rd, 2024 12:00 pm
Foghorn Therapeutics Unveils Clinical Pipeline Progress
- Oct 11th, 2024 11:47 am
Scroll